drugset

drugset / Trial / NCT00237913

Schizophrenia Trial of Aripiprazole

NCT00237913 ↗

Phase 3 Completed 700 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Timeline

Start: 2004-07
Primary completion: 2005-08
Completion: 2005-08

Publications

Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008 Dec 22;8:95. doi: 10.1186/1471-244X-8-95.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aripiprazole	Other / unclassified	10 mg	Oral
Comparator	Aripiprazole	Other / unclassified	30 mg	Oral
Comparator	Olanzapine	Small molecule	5 mg	Oral
Comparator	Olanzapine	Small molecule	20 mg	Oral
Comparator	Quetiapine	Small molecule	100 mg	Oral
Comparator	Quetiapine	Small molecule	800 mg	Oral
Comparator	Risperidone	Other / unclassified	2 mg	Oral
Comparator	Risperidone	Other / unclassified	8 mg	Oral

Indications